Globus Medical, Inc. (NYSE:GMED) Stock Position Lessened by Global Alpha Capital Management Ltd.

Global Alpha Capital Management Ltd. decreased its position in shares of Globus Medical, Inc. (NYSE:GMED) by 7.4% in the fourth quarter, HoldingsChannel reports. The fund owned 819,391 shares of the medical device company’s stock after selling 65,750 shares during the quarter. Globus Medical makes up 4.9% of Global Alpha Capital Management Ltd.’s portfolio, making the stock its 3rd largest position. Global Alpha Capital Management Ltd.’s holdings in Globus Medical were worth $67,772,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in shares of Globus Medical during the fourth quarter worth about $27,000. Quarry LP boosted its stake in Globus Medical by 698.4% in the 3rd quarter. Quarry LP now owns 495 shares of the medical device company’s stock worth $35,000 after purchasing an additional 433 shares in the last quarter. UMB Bank n.a. grew its position in Globus Medical by 60.2% during the 4th quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock worth $45,000 after purchasing an additional 206 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Globus Medical by 230.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after purchasing an additional 385 shares in the last quarter. Finally, V Square Quantitative Management LLC raised its holdings in shares of Globus Medical by 52.0% in the fourth quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company’s stock worth $48,000 after buying an additional 197 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GMED has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Friday, February 21st. Barclays lifted their price target on Globus Medical from $100.00 to $103.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. StockNews.com lowered Globus Medical from a “buy” rating to a “hold” rating in a report on Wednesday. Stifel Nicolaus lifted their target price on Globus Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group upped their target price on Globus Medical from $92.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.82.

Globus Medical Trading Up 1.5 %

Shares of NYSE:GMED opened at $77.48 on Friday. Globus Medical, Inc. has a 12-month low of $49.33 and a 12-month high of $94.93. The business has a 50 day moving average of $85.90 and a two-hundred day moving average of $79.63. The company has a market capitalization of $10.66 billion, a PE ratio of 103.31, a PEG ratio of 1.61 and a beta of 1.19.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million during the quarter, compared to analyst estimates of $646.19 million. Equities research analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.